Lessons from Genomic Profiling in AS

Fernando M Pimentel-Santos, Jaime C Branco, Gethin Thomas

    Research output: Book chapter/Published conference paperOther chapter contribution


    Ankylosing Spondylitis (AS) is a common cause of chronic inflammatory arthritisworldwide, with a prevalence of 0.2-0.9% in white European populations (Braun et al., 1998),with unknown etiology. The progressive ankylosis of affected joints is currently irreversible and it is, therefore, logical that early diagnosis and treatment offers the best opportunity to improve its prognosis. Several studies have shown a delay of more than 8 years between the onset of symptoms and diagnosis, with consequent delay in starting an effective therapy (Feldtkeller et al., 2003; Hamilton et al., 2011). This is a critical period clinically, with diagnosis frequently occurring after significant irreversible radiological damage has already occurred. Currently, diagnosis of AS relies on a combination of clinical and imaging parameters (van der Linden et al., 1984 and Boonen et al., 2010) with no single blood derived biomarker that by itself is sufficiently sensitive and specific to identify AS cases or to be useful in disease management.
    Original languageEnglish
    Title of host publicationClinical and Molecular Advances in Ankylosing Spondylitis
    EditorsJacome Bruges-Armas
    Number of pages30
    ISBN (Print)978-953-51-0137-6
    Publication statusPublished - 2012


    Dive into the research topics of 'Lessons from Genomic Profiling in AS'. Together they form a unique fingerprint.

    Cite this